Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo's Oral Semaglutide Passes PIONEER 2, But Weight Loss Result A Bit Disappointing

Executive Summary

In second Phase III diabetes study to report, oral GLP-1 agonist semaglutide misses some weight loss goals when compared with Boehringer/Lilly's SGLT-2 inhibitor Jardiance.

You may also be interested in...



Seeking Efficiencies, Novo Nordisk To Squeeze Costs, Boost Growth Drivers

Novo Nordisk aims to offset US pricing pressures with increased cost management, freeing investment for key growth drivers like Ozempic and oral Semaglutide.

Novo Nordisk: Switch To Weekly Ozempic Has Begun, Biopharma M&A Sought

But elephant in the room –  the coming stream of readouts from Phase III PIONEER trials on oral semaglutide  in Type 2 diabetes – gets little mention at first-quarter update.

Novo Nordisk Already Plans A 'Next Generation' Oral Semaglutide - CEO

Planned next generation of oral semaglutide 'is in the early research stage', Lars Fruergaard Jorgensen tells Scrip.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS012935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel